Epizyme, Inc.
(NASDAQ : EPZM)

( )
EPZM PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.53%87.991.3%$894.47m
AMGNAmgen Inc.
0.04%191.311.2%$560.48m
ONCESpark Therapeutics, Inc.
0.33%113.9611.2%$458.43m
GILDGilead Sciences, Inc.
-0.93%65.020.9%$450.52m
BIIBBiogen Inc.
-1.28%325.651.3%$354.96m
BPTHBio-Path Holdings, Inc.
-5.48%27.79190.1%$296.94m
REGNRegeneron Pharmaceuticals, Inc.
-1.66%407.602.6%$280.72m
ILMNIllumina, Inc.
-1.31%305.783.5%$269.47m
VRTXVertex Pharmaceuticals Incorporated
-0.32%187.481.9%$245.27m
SRPTSarepta Therapeutics, Inc.
-1.20%126.8215.4%$210.77m
EXASExact Sciences Corporation
-3.44%91.9325.3%$194.56m
ALXNAlexion Pharmaceuticals, Inc.
-1.90%133.512.0%$181.24m
AAgilent Technologies, Inc.
-0.16%80.971.6%$153.74m
IONSIonis Pharmaceuticals, Inc.
1.25%79.528.3%$101.55m
BMRNBioMarin Pharmaceutical Inc.
-1.24%93.364.3%$97.41m

Company Profile

Epizyme, Inc. is a clinical-stage biopharmaceutical company, which engage in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. It also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.